Page 75 - Fisica In Medicina n° 1/2017

^Äëíê~Åí=jÉÇáÅá= =specific antigen (PSA) was 6.1 ng/ml (range: 3.4-12.8 ng/ml). Median Gleason score was 6 (6-7). IPSS pre-SBRT was registered for all patients, with a median value of 4 (range: 0-10). All patients completed the treatment as planned. Acute genitourinary (GU) toxicity was: G0 29/42, G1 7/42, G2 6/42. Acute gastrointestinal (GI) toxicity was: G0 36/42, G1 4/42, G2 2/42. No acute toxicities superior or equal to G3 were recorded. Late GU and GI toxicities were mild without severe events: GU-G0 39/42, GU-G1 2/42, GU-G2 1/42; GI-G0 40/42, GI-G1 2/42. At one-year of follow-up, IPSS was recorded in 25/42 patients with a median value of 4.5 (range: 0-18). At the time of analysis, biochemical control was 100%.ConclusionPreliminary analysis of this SBRT phase II prospective study for low-intermediate-risk PC proved to be feasible and tolerable. Longer follow-up is needed to assess late toxicity profiles and clinical outcomes.66